LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Baishideng Publishing Group Inc
Journal: World Journal of Cardiology
Languages: English
Types: Article
Subjects: RC666, Pleiotropic effects, Review, Statins, Endothelial progenitor cells, Ischaemic heart disease, Pleiotropic mechanisms

Classified by OpenAIRE into

mesheuropmc: cardiovascular system
Statins have become a cornerstone of risk modification for ischaemic heart disease patients. A number of studies have shown that they are effective and safe. However studies have observed an early benefit in terms of a reduction in recurrent infarct and or death after a myocardial infarction, prior to any significant change in lipid profile. Therefore, pleiotropic mechanisms, other than lowering lipid profile alone, must account for this effect. One such proposed pleiotropic mechanism is the ability of statins to augment both number and function of endothelial progenitor cells. The ability to augment repair and maintenance of a functioning endothelium may have profound beneficial effect on vascular repair and potentially a positive impact on clinical outcomes in patients with cardiovascular disease. The following literature review will discuss issues surrounding endothelial progenitor cell (EPC) identification, role in vascular repair, factors affecting EPC numbers, the role of statins in current medical practice and their effects on EPC number.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Interv Cardiol 2007; 20: 93-99 [PMID: 17391216 DOI: 10.1111/
    • j.1540-8183.2007.00251.x]
    • J Med 1999; 340: 115-126 [PMID: 9887164 DOI: 10.1056/
    • NEJM199901143400207]
    • endothelial progenitor cells. Circulation 2002; 105: 3017-3024
    • [PMID: 12081997 DOI: 10.1161/01.CIR.0000018166.84319.55]
    • Circulation 2003; 108: 2710-2715 [PMID: 14597586 DOI:
    • 10.1161/01.CIR.0000096490.16596.A6]
    • endothelium in a monocyte chemoattractant protein-1-dependent
    • cells. Circ Res 2003; 93: 980-989 [PMID: 14525810 DOI: 10.1161/01.
    • RES.0000099245.08637.CE]
    • seeded with CD34(+) bone marrow cells. Blood 2000; 95: 581-585
    • [PMID: 10627466]
    • from AC133-positive progenitor cells. Blood 2000; 95: 3106-3112
    • [PMID: 10807776]
    • by circulating progenitor cells. Circulation 2003; 108: 3122-3127
    • [PMID: 14656919 DOI: 10.1161/01.CIR.0000105722.96112.67]
    • vascular function, and cardiovascular risk. N Engl J Med 2003; 348:
    • 593-600 [PMID: 12584367 DOI: 10.1056/NEJMoa022287]
    • cells for neovascularization. Nat Med 1999; 5: 434-438 [PMID:
    • 10202935 DOI: 10.1038/7434]
    • Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:
    • 653-660 [PMID: 12778163 DOI: 10.1038/nm0603-653]
    • 2003; 108: 2511-2516 [PMID: 14581410 DOI: 10.1161/01.CIR.00-
    • atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565
    • [PMID: 16533939 DOI: 10.1001/jama.295.13.jpc60002]
    • 2003; 9: 702-712 [PMID: 12778169 DOI: 10.1038/nm0603-702]
    • endothelial progenitor cells. Exp Cell Res 2008; 314: 430-440
    • [PMID: 18083163 DOI: 10.1016/j.yexcr.2007.11.016]
    • Randomised trial of cholesterol lowering in 4444 patients with
    • Study (4S). Lancet 1994; 344: 1383-1389 [PMID: 7968073]
    • Coronary Prevention Study Group. N Engl J Med 1995; 333:
    • 1301-1307 [PMID: 7566020 DOI: 10.1056/NEJM199511163332001]
    • of cholesterol lowering with simvastatin during 5 years in the
    • Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156:
    • 2085-2092 [PMID: 8862101 DOI: 10.1001/archinte.1996.004401700
    • of data from 90,056 participants in 14 randomised trials of statins.
    • Lancet 2005; 366: 1267-1278 [PMID: 16214597 DOI: 10.1016/
    • S0140-6736(05)67394-1]
    • Circulation 1998; 97: 1440-1445 [PMID: 9576423 DOI: 10.1161/01.
    • CIR.97.15.1440]
    • 1988; 12: 461-480 [PMID: 3294157 DOI: 10.1111/j.1365-2559.1988.
    • tb01967.x]
    • Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential
    • functions before and after T-helper-2-cell differentiation. Nat Rev
    • Immunol 2009; 9: 125-135 [PMID: 19151747 DOI: 10.1038/
    • nri2476]
    • disease. Nat Med 1995; 1: 27-31 [PMID: 7584949 DOI: 10.1038/
    • nm0195-27]
    • progenitor endothelial cells for angiogenesis. Science 1997; 275:
    • 964-967 [PMID: 9020076 DOI: 10.1126/science.275.5302.964]
    • Am J Pathol 1963; 43: 361-367 [PMID: 14057632]
    • physiological and pathological neovascularization. Circ Res 1999;
    • 85: 221-228 [PMID: 10436164 DOI: 10.1161/01.RES.85.3.221]
    • Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674
    • [PMID: 9109485 DOI: 10.1038/386671a0]
    • progenitor cells. Blood 2005; 106: 1525-1531 [PMID: 15905185
    • DOI: 10.1182/blood-2005-04-1509]
    • cells. Blood 1998; 92: 362-367 [PMID: 9657732]
    • Invest 2000; 105: 71-77 [PMID: 10619863 DOI: 10.1172/JCI8071]
    • of VEGFR-2 and AC133 by circulating human CD34(+) cells
    • 2000; 95: 952-958 [PMID: 10648408]
    • Vasc Biol 2008; 28: 1584-1595 [PMID: 18669889 DOI: 10.1161/
    • ATVBAHA.107.155960]
    • use. Circ Res 2012; 110: 624-637 [PMID: 22343557 DOI: 10.1161/
    • CIRCRESAHA.111.243386]
    • the knowledge plateau. Atherosclerosis 2008; 197: 496-503 [PMID:
    • 18249408 DOI: 10.1016/j.atherosclerosis.2007.12.039]
    • Biol 2003; 23: 1185-1189 [PMID: 12714439 DOI: 10.1161/01.
    • ATV.0000073832.49290.B5]
    • and role in vascular biology. Circ Res 2004; 95: 343-353 [PMID:
    • 15321944 DOI: 10.1161/01.RES.0000137877.89448.78]
    • Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker
    • for human hematopoietic stem and progenitor cells. Blood 1997; 90:
    • 5002-5012 [PMID: 9389720]
    • bone marrow CD133(+) cells. Br J Haematol 2001; 115: 186-194
    • [PMID: 11722432 DOI: 10.1046/j.1365-2141.2001.03077.x]
    • identicfiation. Nat Rev Cancer 2006; 6: 835-845 [PMID: 17036040
    • DOI: 10.1038/nrc1971]
    • B. Endothelial outgrowth cells are not derived from CD133+
    • cells or CD45+ hematopoietic precursors. Arterioscler Thromb
    • Vasc Biol 2007; 27: 1572-1579 [PMID: 17495235 DOI: 10.1161/
    • ATVBAHA.107.144972]
    • Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/
    • CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with
    • potent vasoregenerative capacities. Circ Res 2006; 98: e20-e25 [PMID:
    • 16439688 DOI: 10.1161/01.RES.0000205765.28940.93]
    • transient mobilization of VEGFR2(+)AC133(+) endothelial
    • precursor cells. Circ Res 2001; 88: 167-174 [PMID: 11157668 DOI:
    • 10.1161/01.RES.88.2.167]
    • CD34+AC133+VEGFR-2+ cells are not endothelial progenitor
    • Hematol 2007; 35: 1109-1118 [PMID: 17588480 DOI: 10.1016/
    • j.exphem.2007.04.002]
    • One 2010; 5: e13790 [PMID: 21072182 DOI: 10.1371/journal.
    • pone.0013790]
    • 45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome
    • inhibitors. Br J Cancer 2011; 104: 1144-1150 [PMID: 21386843 DOI:
    • 10.1038/bjc.2011.72]
    • repair. Circulation 2005; 111: 2981-2987 [PMID: 15927972 DOI:
    • 10.1161/CIRCULATIONAHA.104.504340]
    • J Am Coll Cardiol 2010; 55: 1553-1565 [PMID: 20378071 DOI:
    • 10.1016/j.jacc.2009.10.070]
    • coronary heart disease. Circulation 2000; 101: 1899-1906 [PMID:
    • 10779454 DOI: 10.1161/01.CIR.101.16.1899]
    • artery disease and endothelial dysfunction. Circulation 2000; 101:
    • 948-954 [PMID: 10704159 DOI: 10.1161/01.CIR.101.9.948]
    • vascular endothelial dysfunction. Circulation 2002; 106: 653-658
    • [PMID: 12163423 DOI: 10.1161/01.CIR.0000025404.78001.D8]
    • study. Circulation 2002; 105: 1567-1572 [PMID: 11927524 DOI:
    • 10.1161/01.CIR.0000012543.55874.47]
    • Stroke 2008; 39: 2158-2165 [PMID: 18451350 DOI: 10.1161/
    • STROKEAHA.107.507251]
    • disease. Clin Sci (Lond) 2011; 120: 263-283 [PMID: 21143202
    • DOI: 10.1042/CS20100429]
    • for regenerative capacity? J Am Coll Cardiol 2003; 42: 2081-2082
    • [PMID: 14680730 DOI: 10.1016/j.jacc.2003.09.016]
    • differing coronary collateral support. Circulation 2004; 109: 2986-2992
    • [PMID: 15184289 DOI: 10.1161/01.CIR.0000130639.97284.EC]
    • factors for coronary artery disease. Circ Res 2001; 89: E1-E7 [PMID:
    • 11440984 DOI: 10.1161/hh1301.093953]
    • F, Simon A. Decreased number of circulating CD34+KDR+ cells in
    • 2007; 191: 115-120 [PMID: 16620831 DOI: 10.1016/j.atherosclerosis.
    • Res Cardiol 2007; 102: 565-571 [PMID: 17932708 DOI: 10.1007/
    • s00395-007-0680-1]
    • and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007
    • [PMID: 16148285 DOI: 10.1056/NEJMoa043814]
    • disease severity. Am Heart J 2006; 152: 190-195 [PMID: 16824855
    • DOI: 10.1016/j.ahj.2006.02.001]
    • chronic coronary artery disease. Heart 2006; 92: 253-254 [PMID:
    • 16415195 DOI: 10.1136/hrt.2004.058636]
    • artery disease. J Am Coll Cardiol 2006; 48: 1579-1587 [PMID:
    • 17045891 DOI: 10.1016/j.jacc.2006.04.101]
    • infarction. Circulation 2001; 103: 2776-2779 [PMID: 11401930
    • DOI: 10.1161/hc2301.092122]
    • Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem
    • myocardial infarction. Circulation 2004; 110: 3213-3220 [PMID:
    • 15533859 DOI: 10.1161/01.CIR.0000147609.39780.02]
    • infarction. Blood 2005; 105: 199-206 [PMID: 15345590 DOI:
    • 10.1182/blood-2004-05-1831]
    • function. Eur Heart J 2005; 26: 1196-1204 [PMID: 15734770 DOI:
    • 10.1093/eurheartj/ehi164]
    • after percutaneous coronary intervention. Atherosclerosis 2006;
    • 189: 70-75 [PMID: 16806234 DOI: 10.1016/j.atherosclerosis.2006.
    • Res 2000; 87: 526-528 [PMID: 11009552 DOI: 10.1161/01.
    • RES.87.7.526]
    • Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-
    • 3-methylglutaryl coenzyme A reductase. Am Heart J 2002; 144:
    • S27-S32 [PMID: 12486413 DOI: 10.1067/mhj.2002.130300]
    • Circulation 2001; 103: 2885-2890 [PMID: 11413075 DOI: 10.1161/
    • hc2401.092816]
    • Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:
    • 1349-1357 [PMID: 9841303 DOI: 10.1056/NEJM199811053391902]
    • J Med 1996; 335: 1001-1009 [PMID: 8801446 DOI: 10.1056/
    • NEJM199610033351401]
    • coronary disease. N Engl J Med 2005; 352: 1425-1435 [PMID:
    • 15755765 DOI: 10.1056/NEJMoa050461]
    • E. Relative efcfiacy of atorvastatin 80 mg and pravastatin 40 mg in
    • achieving the dual goals of low-density lipoprotein cholesterol & lt; 70
    • mg/dl and C-reactive protein & lt; 2 mg/l: an analysis of the PROVE-
    • IT TIMI-22 trial. J Am Coll Cardiol 2005; 45: 1644-1648 [PMID:
    • 15893181 DOI: 10.1016/j.jacc.2005.02.080]
    • JAMA 2001; 285: 1711-1718 [PMID: 11277825 DOI: 10.1001/
    • jama.285.13.1711]
    • Circulation 2000; 101: 207-213 [PMID: 10637210 DOI: 10.1161/01.
    • CIR.101.2.207]
    • thrombogenic potential with cholesterol reduction. Circulation 1995;
    • 92: 3172-3177 [PMID: 7586300 DOI: 10.1161/01.CIR.92.11.3172]
    • randomized controlled trial. JAMA 2004; 291: 1071-1080 [PMID:
    • 14996776 DOI: 10.1001/jama.291.9.1071]
    • analysis of 13 randomized studies. Circulation 2011; 123: 1622-1632
    • [PMID: 21464051 DOI: 10.1161/CIRCULATIONAHA.110.002451]
    • J Am Coll Cardiol 2009; 54: 558-565 [PMID: 19643320 DOI:
    • 10.1016/j.jacc.2009.05.028]
    • RW, Zieman SJ. 2014 AHA/ACC Guideline for the Management
    • Cardiol 2014; 64: e139-e228 [PMID: 25260718 DOI: 10.1016/
    • j.jacc.2014.09.017]
    • EM, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for
    • 2013; 127: e362-e425 [PMID: 23247304 DOI: 10.1161/
    • CIR.0b013e3182742cf6]
    • model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-2064
    • [PMID: 9857893 DOI: 10.1016/S0735-1097(98)00487-2]
    • cerebral ischemia in normocholesterolemic mice. Stroke 2000; 31:
    • 2442-2449 [PMID: 11022078 DOI: 10.1161/01.STR.31.10.2442]
    • 1 diabetes and microalbuminuria. Diabet Med 2005; 22: 239-242
    • [PMID: 15717868 DOI: 10.1111/j.1464-5491.2004.01382.x]
    • Thromb Haemost 2000; 83: 688-692 [PMID: 10823263] 87 Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K,
    • progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;
    • 108: 391-397 [PMID: 11489932 DOI: 10.1172/JCI13152] 88 Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial
    • 1998; 97: 1129-1135 [PMID: 9537338 DOI: 10.1161/01.
    • CIR.97.12.1129] 89 Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa
    • normocholesterolemic animals. Nat Med 2000; 6: 1004-1010
    • [PMID: 10973320 DOI: 10.1038/79510] 90 Laufs U, Liao JK. Post-transcriptional regulation of endothelial
    • Chem 1998; 273: 24266-24271 [PMID: 9727051 DOI: 10.1074/
    • jbc.273.37.24266] 91 Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C,
    • progenitor cells. Nat Med 2003; 9: 1370-1376 [PMID: 14556003
    • DOI: 10.1038/nm948] 92 Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H,
    • cells. J Clin Invest 2001; 108: 399-405 [PMID: 11489933 DOI:
    • 10.1172/JCI13131] 93 Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and
    • thrombolysis. FASEB J 1990; 4: 3087-3098 [PMID: 2210155] 94 Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged
    • role of statins in angiogenesis signaling. Circ Res 2002; 90: 737-744
    • [PMID: 11934843 DOI: 10.1161/01.RES.0000014081.30867.F8] 95 Deschaseaux F, Selmani Z, Falcoz PE, Mersin N, Meneveau N,
    • CoA reductase inhibitors. Eur J Pharmacol 2007; 562: 111-118
    • [PMID: 17320859 DOI: 10.1016/j.ejphar.2007.01.045] 96 Hristov M, Fach C, Becker C, Heussen N, Liehn EA, Blindt R,
    • with long-term statin treatment. Atherosclerosis 2007; 192: 413-420
    • [PMID: 16837000 DOI: 10.1016/j.atherosclerosis.2006.05.031] 97 Lin LY, Huang CC, Chen JS, Wu TC, Leu HB, Huang PH, Chang
    • blind, randomized study. Cardiovasc Diabetol 2014; 13: 111 [PMID:
    • 25027585 DOI: 10.1186/s12933-014-0111-1] 98 Leone AM, Rutella S, Giannico MB, Perfetti M, Zaccone V,
    • and PCI (STRAP) trial. Int J Cardiol 2008; 130: 457-462 [PMID:
    • 18667247 DOI: 10.1016/j.ijcard.2008.05.036] 99 Ye H, He F, Fei X, Lou Y, Wang S, Yang R, Hu Y, Chen X.
    • period. J Cardiovasc Pharmacol Ther 2014; 19: 290-295 [PMID:
    • 24346155 DOI: 10.1177/1074248413513500] 100 Ricottini EMR, Patti G. Benefit of atorvastatin reload on endo-
    • undergoing PCI. J Am Coll Cardiol 2013; 61: 10 [DOI: 10.1016/
    • S0735-1097(13)61635-6] 101 Knowles RG, Moncada S. Nitric oxide synthases in mammals.
    • Biochem J 1994; 298 (Pt 2): 249-258 [PMID: 7510950 DOI:
    • 10.1042/bj2980249] 102 Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl
    • J Med 1993; 329: 2002-2012 [PMID: 7504210 DOI: 10.1056/
    • NEJM199312303292706] 103 Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res
    • 1994; 31: 131-143 [PMID: 7511942 DOI: 10.1159/000159039] 104 Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology,
    • pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:
    • 109-142 [PMID: 1852778] 105 Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS,
    • Thromb Vasc Biol 1997; 17: 2479-2488 [PMID: 9409218 DOI:
    • 10.1161/01.ATV.17.11.2479] 106 Stuehr DJ, Griffith OW. Mammalian nitric oxide synthases. Adv
    • Enzymol Relat Areas Mol Biol 1992; 65: 287-346 [PMID: 1373932
    • DOI: 10.1002/9780470123119.ch8] 107 Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher
    • dependent phosphorylation. Nature 1999; 399: 601-605 [PMID:
    • 10376603 DOI: 10.1038/21224] 108 Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R.
    • Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-
    • dependent endothelial nitric oxide synthase activity. Circ Res 2001;
    • 88: E68-E75 [PMID: 11397791 DOI: 10.1161/hh1101.092677] 109 Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia
    • inactivate endothelium-derived relaxing factor. Am J Physiol 1986;
    • 250: H822-H827 [PMID: 3010744] 110 Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat
    • Med 2000; 6: 389-395 [PMID: 10742145 DOI: 10.1038/74651] 111 Carmeliet P, Jain RK. Angiogenesis in cancer and other dis-
    • eases. Nature 2000; 407: 249-257 [PMID: 11001068 DOI:
    • 10.1038/35025220] 112 Semenza GL. Vasculogenesis, angiogenesis, and arteriogenesis:
    • Biochem 2007; 102: 840-847 [PMID: 17891779 DOI: 10.1002/
    • jcb.21523] 113 Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia.
    • J Vasc Surg 2003; 38: 198-203 [PMID: 12844115 DOI: 10.1016/
    • S0741-5214(03)00151-4] 114 Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A,
    • synthase. Circulation 2004; 110: 1933-1939 [PMID: 15466656 DOI:
    • 10.1161/01.CIR.0000143232.67642.7A] 115 Matsuno H, Takei M, Hayashi H, Nakajima K, Ishisaki A, Kozawa
    • VEGF secretion in injured arteries. J Cardiovasc Pharmacol 2004;
    • 43: 333-340 [PMID: 15076215 DOI: 10.1097/00005344-20040300
    • 0-00002] 116 Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density
    • synthase. J Biol Chem 1995; 270: 319-324 [PMID: 7529227 DOI:
    • 10.1074/jbc.270.1.319] 117 Liao JK, Clark SL. Regulation of G-protein alpha i2 subunit
    • expression by oxidized low-density lipoprotein. J Clin Invest 1995;
    • 95: 1457-1463 [PMID: 7706449 DOI: 10.1172/JCI117816] 118 Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi
    • vasodilatation in hypercholesterolemic humans. Circulation 1997;
    • 95: 76-82 [PMID: 8994420 DOI: 10.1161/01.CIR.95.1.76] 119 López-Farré A, Caramelo C, Esteban A, Alberola ML, Millás
    • interactions. Role of nitric oxide and endothelin-1. Circulation 1995;
    • 91: 2080-2088 [PMID: 7895367 DOI: 10.1161/01.CIR.91.7.2080] 120 Latini R, Bianchi M, Correale E, Dinarello CA, Fantuzzi G, Fresco
    • necrosis factor, its soluble receptor, and interleukin-1 receptor
    • antagonist. J Cardiovasc Pharmacol 1994; 23: 1-6 [PMID: 7511719
    • DOI: 10.1097/00005344-199401000-00001] 121 Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric
    • neutrophil adherence to coronary endothelium. Circ Res 1993; 72:
    • 403-412 [PMID: 8418991 DOI: 10.1161/01.RES.72.2.403] 122 Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J,
    • genes. Circ Res 2003; 92: 1049-1055 [PMID: 12676819 DOI:
    • 10.1161/01.RES.0000070067.64040.7C] 123 Kusuyama T, Omura T, Nishiya D, Enomoto S, Matsumoto R,
    • J Pharmacol Sci 2006; 101: 344-349 [PMID: 16891763 DOI:
    • 10.1254/jphs.FP0060102] 124 Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-
    • Chem 1997; 272: 31725-31729 [PMID: 9395516 DOI: 10.1074/
    • jbc.272.50.31725] 125 Davis ME, Cai H, McCann L, Fukai T, Harrison DG. Role of
    • 2003; 284: H1449-H1453 [PMID: 12595302 DOI: 10.1152/
    • ajpheart.00918.2002] 126 Kosmidou I, Moore JP, Weber M, Searles CD. Statin treatment
    • and 3' polyadenylation of eNOS mRNA. Arterioscler Thromb
    • Vasc Biol 2007; 27: 2642-2649 [PMID: 17916773 DOI: 10.1161/
    • ATVBAHA.107.154492] 127 Minami Y, Satoh M, Maesawa C, Takahashi Y, Tabuchi T, Itoh
    • T, Nakamura M. Effect of atorvastatin on microRNA 221 / 222
    • with coronary artery disease. Eur J Clin Invest 2009; 39: 359-367
    • [PMID: 19371267 DOI: 10.1111/j.1365-2362.2009.02110.x] 128 Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs
    • repress translation after initiation in mammalian cells. Mol Cell 2006;
    • 21: 533-542 [PMID: 16483934 DOI: 10.1016/j.molcel.2006.01.031] 129 Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi
    • Sorrentino A, Croce CM, Peschle C. MicroRNAs 221 and 222
    • kit receptor down-modulation. Proc Natl Acad Sci U S A 2005; 102:
    • 18081-18086 [PMID: 16330772 DOI: 10.1073/pnas.0506216102] 130 Cerda A, Fajardo CM, Basso RG, Hirata MH, Hirata RD. Role of
    • microRNAs 221/222 on statin induced nitric oxide release in human
    • endothelial cells. Arq Bras Cardiol 2015; 104: 195-201 [PMID:
    • 25517390 DOI: 10.5935/abc.20140192] 131 Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA
    • expression to regulate angiogenesis. Trends Pharmacol Sci 2008;
    • 29: 12-15 [PMID: 18068232 DOI: 10.1016/j.tips.2007.10.014] 132 Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates
    • transcription and translation. Nat Rev Cancer 2005; 5: 921-929
    • [PMID: 16341083 DOI: 10.1038/nrc1753] 133 Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis
    • signaling. Circ Res 2000; 86: 4-5 [PMID: 10625297 DOI:
    • 10.1161/01.RES.86.1.4] 134 Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I
    • phosphatidylinositol-3-phosphate. Nature 1988; 332: 644-646
    • [PMID: 2833705 DOI: 10.1038/332644a0] 135 Toker A, Cantley LC. Signalling through the lipid products of
    • phosphoinositide-3-OH kinase. Nature 1997; 387: 673-676 [PMID:
    • 9192891 DOI: 10.1038/42648] 136 Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis.
    • Front Mol Neurosci 2011; 4: 51 [PMID: 22144946 DOI: 10.3389/
    • fnmol.2011.00051] 137 Kawasaki K, Smith RS, Hsieh CM, Sun J, Chao J, Liao JK.
    • Activation of the phosphatidylinositol 3-kinase/protein kinase Akt
    • and angiogenesis. Mol Cell Biol 2003; 23: 5726-5737 [PMID:
    • 12897144 DOI: 10.1128/MCB.23.16.5726-5737.2003] 138 Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of
    • anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591 [PMID:
    • 18596824 DOI: 10.1038/nrc2403] 139 Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh
    • serine/threonine kinase Akt. Circ Res 2000; 86: 892-896 [PMID:
    • 10785512 DOI: 10.1161/01.RES.86.8.892] 140 Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC.
    • Clin Invest 1997; 100: 3131-3139 [PMID: 9399960 DOI: 10.1172/
    • JCI119868] 141 Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh
    • kinase Akt. Nature 1999; 399: 597-601 [PMID: 10376602 DOI:
    • 10.1038/21218] 142 Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the
    • endothelial nitric oxide synthase at ser-1177 is required for VEGF-
    • induced endothelial cell migration. FEBS Lett 2000; 477: 258-262
    • [PMID: 10908731 DOI: 10.1016/S0014-5793(00)01657-4] 143 Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B,
    • regulates endothelial progenitor cells. Blood 2004; 103: 921-926
    • [PMID: 14525788 DOI: 10.1182/blood-2003-04-1284] 144 Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ
    • Res 2005; 97: 1232-1235 [PMID: 16339495 DOI: 10.1161/01.
    • RES.0000196564.18314.23] 145 Lemoine S, Zhu L, Legallois D, Massetti M, Manrique A, Hanouz
    • 2013; 118: 1373-1384 [PMID: 23416384 DOI: 10.1097/ALN.0b013-
    • e31828a7039] 146 Sanada S, Asanuma H, Minamino T, Node K, Takashima S, Okuda
    • of statin use for immediate infarct limitation: 5'-nucleotidase as
    • another downstream molecule of phosphatidylinositol 3-kinase.
    • Circulation 2004; 110: 2143-2149 [PMID: 15451788 DOI:
    • 10.1161/01.CIR.0000143830.59419.73] 147 Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endo-
    • Physiol 2006; 290: H441-H449 [PMID: 16155103 DOI: 10.1152/
    • ajpheart.00589.2005] 148 Hausenloy DJ, Yellon DM. New directions for protecting the heart
    • Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61:
    • 448-460 [PMID: 14962476 DOI: 10.1016/j.cardiores.2003.09.024] 149 Efthymiou CA, Mocanu MM, Yellon DM. Atorvastatin and
    • multiple prosurvival signaling. J Cardiovasc Pharmacol 2005;
    • 45: 247-252 [PMID: 15725950 DOI: 10.1097/01.fjc.000-
    • 0154376.82445.06] 150 Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, Chen
    • on healing of stented human arteries. PLoS One 2011; 6: e16413
    • [PMID: 21283543 DOI: 10.1371/journal.pone.0016413] 151 Baran Ç, Durdu S, Dalva K, Zaim Ç, Dogan A, Ocakoglu G,
    • surgery: a randomized, controlled trial. Stem Cell Rev 2012; 8:
    • 963-971 [PMID: 22076751 DOI: 10.1007/s12015-011-9321-z] 152 Schmidt-Lucke C, Fichtlscherer S, Rössig L, Kämper U, Dimmeler
    • patients with coronary artery disease after 4 weeks of statin therapy.
    • Atherosclerosis 2010; 211: 249-254 [PMID: 20211468 DOI:
    • 10.1016/j.atherosclerosis.2010.02.007] 153 Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos
    • of inaflmmatory process and oxidative stress. Atherosclerosis 2011;
    • 214: 151-157 [PMID: 21122851 DOI: 10.1016/j.atherosclerosis.201
    • 0.11.002] 154 Jialal I, Devaraj S, Singh U, Huet BA. Decreased number and
    • risk. Atherosclerosis 2010; 211: 297-302 [PMID: 20171637 DOI:
    • 10.1016/j.atherosclerosis.2010.01.036] 155 C o h e n M V , Ya n g X M , D o w n e y J M . N i t r i c o x i d e i s a
    • many available infarct-sparing strategies. Cardiovasc Res 2006; 70:
    • 231-239 [PMID: 16376869 DOI: 10.1016/j.cardiores.2005.10.021] 156 Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM,
    • apolipoprotein E-decfiient mice. Circulation 2001; 103: 2598-2603
    • [PMID: 11382730 DOI: 10.1161/01.CIR.103.21.2598] 157 Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K,
    • Vasc Biol 2002; 22: 300-305 [PMID: 11834532 DOI: 10.1161/
    • hq0202.104081] 158 Mensah K, Mocanu MM, Yellon DM. Failure to protect the
    • chromosome ten? J Am Coll Cardiol 2005; 45: 1287-1291 [PMID:
    • 15837263 DOI: 10.1016/j.jacc.2005.01.021] 159 Mihos CG, Pineda AM, Santana O. Cardiovascular effects of
    • statins, beyond lipid-lowering properties. Pharmacol Res 2014; 88:
    • 12-19 [PMID: 24631782 DOI: 10.1016/j.phrs.2014.02.009] 160 Tousoulis D, Andreou I, Antoniades C, Tentolouris C, Stefanadis C.
    • cardiovascular diseases. Atherosclerosis 2008; 201: 236-247 [PMID:
    • 18599065 DOI: 10.1016/j.atherosclerosis.2008.05.034] 161 Yao EH, Yu Y, Fukuda N. Oxidative stress on progenitor and stem
    • cells in cardiovascular diseases. Curr Pharm Biotechnol 2006; 7:
    • 101-108 [PMID: 16724944 DOI: 10.2174/138920106776597685] 162 Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth
    • oxidation. Arteriosclerosis 1984; 4: 357-364 [PMID: 6466193 DOI:
    • 10.1161/01.ATV.4.4.357] 163 Lamb DJ, Wilkins GM, Leake DS. The oxidative modicfiation of low
    • density lipoprotein by human lymphocytes. Atherosclerosis 1992; 92:
    • 187-192 [PMID: 1632847 DOI: 10.1016/0021-9150(92)90277-N] 164 Lim S, Barter P. Antioxidant effects of statins in the management
    • of cardiometabolic disorders. J Atheroscler Thromb 2014; 21:
    • 997-1010 [PMID: 25132378 DOI: 10.5551/jat.24398] 165 Carracedo J, Merino A, Briceño C, Soriano S, Buendía P,
    • FASEB J 2011; 25: 1314-1322 [PMID: 21228221 DOI: 10.1096/
    • fj.10-173377] 166 Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-
    • repair in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1144-1149
    • [PMID: 16528007 DOI: 10.1161/01.ATV.0000216600.37436.cf] 167 Griendling KK, FitzGerald GA. Oxidative stress and cardiovas-
    • 2003; 108: 2034-2040 [PMID: 14581381 DOI: 10.1161/01.
    • CIR.0000093661.90582.c4] 168 Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P,
    • mobilization and function in diabetes. Diabetes 2007; 56: 666-674
    • [PMID: 17327434 DOI: 10.2337/db06-0699] 169 Urbich C, Knau A, Fichtlscherer S, Walter DH, Brühl T, Potente
    • 2005; 19: 974-976 [PMID: 15824087 DOI: 10.1096/fj.04-2727fje] 170 Fleissner F, Thum T. Critical role of the nitric oxide/reactive
    • Antioxid Redox Signal 2011; 15: 933-948 [PMID: 20712407 DOI:
    • 10.1089/ars.2010.3502] 171 Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ,
    • 2002; 106: 2781-2786 [PMID: 12451003 DOI: 10.1161/01.
    • CIR.0000039526.42991.93] 172 Tao J, Yang Z, Wang JM, Wang LC, Luo CF, Tang AL, Dong
    • 2007; 21: 353-358 [PMID: 17287843 DOI: 10.1038/sj.jhh.1002147] 173 He T, Peterson TE, Holmuhamedov EL, Terzic A, Caplice NM,
    • Biol 2004; 24: 2021-2027 [PMID: 15319267 DOI: 10.1161/01.
    • ATV.0000142810.27849.8f] 174 Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM,
    • stress. Blood 2004; 104: 3591-3597 [PMID: 15161665 DOI:
    • 10.1182/blood-2003-12-4103] 175 Endres M. Statins: potential new indications in inflammatory
    • conditions. Atheroscler Suppl 2006; 7: 31-35 [PMID: 16503422
    • DOI: 10.1016/j.atherosclerosissup.2006.01.005] 176 Bauer SM, Goldstein LJ, Bauer RJ, Chen H, Putt M, Velazquez OC.
    • impaired in delayed wound healing from ischemia. J Vasc Surg 2006;
    • 43: 134-141 [PMID: 16414400 DOI: 10.1016/j.jvs.2005.08.038] 177 Masuda H, Kalka C, Takahashi T, Yoshida M, Wada M, Kobori M,
    • physiological postnatal vasculogenesis. Circ Res 2007; 101: 598-606
    • [PMID: 17656679 DOI: 10.1161/CIRCRESAHA.106.144006] 178 Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T,
    • via “imported” nitric oxide synthase activity. Circulation 2005; 111:
    • 1114-1120 [PMID: 15723985 DOI: 10.1161/01.CIR.0000157144.
    • 24888.7E] 179 Zhang Y, Devries ME, Skolnick J. Structure modeling of all
    • Comput Biol 2006; 2: e13 [PMID: 16485037 DOI: 10.1371/journal.
    • pcbi.0020013] 180 Bjarnadóttir TK, Gloriam DE, Hellstrand SH, Kristiansson
    • and mouse. Genomics 2006; 88: 263-273 [PMID: 16753280 DOI:
    • 10.1016/j.ygeno.2006.04.001] 181 Schöneberg T, Hofreiter M, Schulz A, Römpler H. Learning from
    • the past: evolution of GPCR functions. Trends Pharmacol Sci 2007;
    • 28: 117-121 [PMID: 17280721 DOI: 10.1016/j.tips.2007.01.001] 182 Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane
    • receptors. Nat Rev Mol Cell Biol 2002; 3: 639-650 [PMID:
    • 12209124 DOI: 10.1038/nrm908] 183 Perez DM. The evolutionarily triumphant G-protein-coupled
    • receptor. Mol Pharmacol 2003; 63: 1202-1205 [PMID: 12761327
    • DOI: 10.1124/mol.63.6.1202] 184 Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and
    • function of G-protein-coupled receptors. Nature 2009; 459: 356-363
    • [PMID: 19458711 DOI: 10.1038/nature08144] 185 Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF,
    • Nature 2013; 494: 185-194 [PMID: 23407534 DOI: 10.1038/
    • nature11896] 186 Callihan P, Mumaw J, Machacek DW, Stice SL, Hooks SB.
    • protein coupled receptors. Pharmacol Ther 2011; 129: 290-306
    • [PMID: 21073897 DOI: 10.1016/j.pharmthera.2010.10.007] 187 Kobayashi NR, Hawes SM, Crook JM, Pébay A. G-protein
    • Stem Cell Rev 2010; 6: 351-366 [PMID: 20625855 DOI: 10.1007/
    • s12015-010-9167-9] 188 Nature Reviews Drug Discovery GPCR Questionnaire Partici-
    • pants. The state of GPCR research in 2004. Nat Rev Drug Discov
    • 2004; 3: 575, 577-626 [PMID: 15272499 DOI: 10.1038/nrd1458] 189 Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM
    • G-protein-coupled receptor target family. ChemMedChem 2006; 1:
    • 761-782 [PMID: 16902930 DOI: 10.1002/cmdc.200600134] 190 Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman
    • AG, Bollag G, Sternweis PC. p115 RhoGEF, a GTPase activating
    • protein for Galpha12 and Galpha13. Science 1998; 280: 2109-2111
    • [PMID: 9641915 DOI: 10.1126/science.280.5372.2109] 191 Noma K, Oyama N, Liao JK. Physiological role of ROCKs in
    • the cardiovascular system. Am J Physiol Cell Physiol 2006; 290:
    • C661-C668 [PMID: 16469861 DOI: 10.1152/ajpcell.00459.2005] 192 Taussig R, Iñiguez-Lluhi JA, Gilman AG. Inhibition of adenylyl
    • cyclase by Gi alpha. Science 1993; 261: 218-221 [PMID: 8327893
    • DOI: 10.1126/science.8327893] 193 Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling
    • in the vascular system. Cardiovasc Res 2009; 82: 261-271 [PMID:
    • 19038971 DOI: 10.1093/cvr/cvn325] 194 Gilman AG. G proteins: transducers of receptor-generated signals.
    • Annu Rev Biochem 1987; 56: 615-649 [PMID: 3113327 DOI:
    • 10.1146/annurev.bi.56.070187.003151] 195 Ghanemi A. Targeting G protein coupled receptor-related pathways
    • as emerging molecular therapies. Saudi Pharm J 2015; 23: 115-129
    • [PMID: 25972730 DOI: 10.1016/j.jsps.2013.07.007] 196 Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for
    • new therapeutic interventions. Ann Med 2004; 36: 204-214 [PMID:
    • 15181976 DOI: 10.1080/07853890310024668] 197 Lynch JR, Wang JY. G Protein-Coupled Receptor Signaling in
    • Stem Cells and Cancer. Int J Mol Sci 2016; 17: [PMID: 27187360
    • DOI: 10.3390/ijms17050707]
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article